The DOI matches its Crossref record; 44 of the 46 references it cites were found in a registry or an index.
Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features
Open accessAbstract
Background & aims Agents that induce an immune response against tumors by altering T-cell regulation have increased survival times of patients with advanced-stage tumors, such as melanoma or lung cancer. We aimed to characterize molecular features of immune cells that infiltrate hepatocellular carcinomas (HCCs) to determine whether these types of agents might be effective against liver tumors.Methods We analyzed HCC samples from 956 patients. We separated gene expression profiles from tumor, stromal, and immune cells using a non-negative matrix factorization algorithm. We then analyzed the gene expression pattern of inflammatory cells in HCC tumor samples. We correlated expression patterns with the presence of immune cell infiltrates and immune regulatory molecules, determined by pathology and immunohistochemical analyses, in a training set of 228 HCC samples. We validated the correlation in a validation set of 728 tumor samples. Using data from 190 tumors in the Cancer Genome Atlas, we correlated immune cell gene expression profiles with numbers of chromosomal aberrations (based on single-nucleotide polymorphism array) and mutations (exome sequence data).Results We found approximately 25% of HCCs to have markers of an inflammatory response, with high expression levels of the CD274 molecule (programmed death-ligand 1) and programmed cell death 1, markers of cytolytic activity, and fewer chromosomal aberrations. We called this group of tumors the Immune class. It contained 2 subtypes, characterized by markers of an adaptive T-cell response or exhausted immune response. The exhausted immune response subclass expressed many genes regulated by transforming growth factor beta 1 that mediate immunosuppression. We did not observe any differences in numbers of mutations or expression of tumor antigens between the immune-specific class and other HCCs.Conclusions In an analysis of HCC samples from 956 patients, we found almost 25% to express markers of an inflammatory response. We identified 2 subclasses, characterized by adaptive or exhausted immune responses. These findings indicate that some HCCs might be susceptible to therapeutic agents designed to block the regulatory pathways in T cells, such as programmed death-ligand 1, programmed cell death 1, or transforming growth factor beta 1 inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Inflamed tumours constitute ~30% of HCCs and exhibit extensive immune cell infiltration and immune activity, detected as increased expression of immune checkpoints (such as PD-1 or its ligand PD-L1), activation of IFN signalling and a low burden of large chromosomal alterations70,71,78.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [71]
The cited source says what the claim attributes to it.
In the citing paper
“Furthermore, a high TMB does not correlate with increased immune infiltration70,71.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [71]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Self-citationSafety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Inferring tumour purity and stromal and immune cell admixture from expression data
Yoshihara, K., Shahmoradgoli, M., Martínez, E., Vegesna, R., Kim, H., Torres-Garcia, W., Treviño, V., Shen, H., Laird, P. W., Levine, D. A., et al. (2013) · Nature Communications · doi:10.1038/ncomms3612 · Cited by 9,778
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Murray, C. J. L., Vos, T., Lozano, R., Naghavi, M., Flaxman, A. D., Michaud, C., Ezzati, M., Shibuya, K., Salomon, J. A., Abdalla, S., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61689-4 · Cited by 8,888
Herbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
Sorafenib in Advanced Hepatocellular Carcinoma
정, 재. (2008) · Cited by 5,586
Charoentong, P., Finotello, F., Angelova, M., Mayer, C., Efremova, M., Rieder, D., Hackl, H., & Trajanoski, Z. (2017) · Cell Reports · doi:10.1016/j.celrep.2016.12.019 · Cited by 5,041
Flagged first, then by citations
2 of the 46 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 401–500 of 1,000
Personeni, N., Pressiani, T., D’Alessio, A., Prete, M. G., Bozzarelli, S., Terracciano, L., Buono, A. D., Capogreco, A., Aghemo, A., Lleò, A., et al. (2021) · Cancers · doi:10.3390/cancers13225665 · Cited by 17
Exonuclease 1 is a Potential Diagnostic and Prognostic Biomarker in Hepatocellular Carcinoma
Ma, J., Jin, J., Lu, H., Zhang, J., Li, Y., & Cai, X.-F. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.889414 · Cited by 17
The Emerging Role of Ferroptosis in Liver Cancers
Casini, A., Leone, S., Vaccaro, R., Vivacqua, G., Ceci, L., Pannarale, L., Franchitto, A., Onori, P., Gaudio, E., & Mancinelli, R. (2022) · Life · doi:10.3390/life12122128 · Cited by 17
Zadran, B., Sudhindar, P. D., Wainwright, D., Bury, Y. A., Luli, S., Howarth, R., McCain, M. V., Watson, R., Huet, H., Palinkas, F., et al. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02154-9 · Cited by 17
Li, H., Li, J., Zhang, Z., Yang, Q., Du, H., Dong, Q., Guo, Z. Y., Yao, J., Li, S., Li, D., et al. (2024) · Advanced Science · doi:10.1002/advs.202410120 · Cited by 17
Tsai, C.-L., Chang, J., Yu, M., Lee, C., Chen, T., Chuang, W., Kuo, W.-L., Lin, C., Lin, S., & Hsieh, S. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3531 · Cited by 17
Heinrich, S., Castven, D., Galle, P. R., & Marquardt, J. U. (2020) · Cancers · doi:10.3390/cancers12092495 · Cited by 18
Tao, P., Hong, L., Tang, W., Lü, Q., Zhao, Y., Zhang, S., Ma, L., & Xue, R. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.574778 · Cited by 17
Mechanisms of Pharmacoresistance in Hepatocellular Carcinoma: New Drugs but Old Problems
Marı́n, J. J. G., Romero, M. R., Herráez, E., Asensio, M., Ortiz-Rivero, S., Sánchez-Martín, A., Fabris, L., & Briz, Ó. (2021) · Seminars in Liver Disease · doi:10.1055/s-0041-1735631 · Cited by 18
Huang, H., Hu, Y., Guo, L., & Wen, Z. (2021) · Oncology Letters · doi:10.3892/ol.2021.13091 · Cited by 17
Intrinsic and Extrinsic Control of Hepatocellular Carcinoma by TAM Receptors
Hedrich, V., Breitenecker, K., Djerlek, L., Ortmayr, G., & Mikulits, W. (2021) · Cancers · doi:10.3390/cancers13215448 · Cited by 17
Tang, H. J., You, T., Sun, Z., Bai, C., & Wang, Y. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.839806 · Cited by 17
Immune-based identification of cancer patients at high risk of progression
Vano, Y. A., Petitprez, F., Giraldo, N. A., Fridman, W. H., & Sautès‐Fridman, C. (2018) · Current Opinion in Immunology · doi:10.1016/j.coi.2018.03.005 · Cited by 17
Zhao, X., Liu, B., William, W. N., Tsanov, K. M., Ho, Y.-J., Barriga, F. M., Lim, R. J., Trifas, M., Khandekar, A., Du, Y., et al. (2024) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2024.12.020 · Cited by 19
Lyu, X., Li, G., & Qiao, Q. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-021-02845-y · Cited by 16
Dong, F., Yang, Q., Wu, Z., Hu, X.-N., Shi, D.-M., Feng, M., Li, J., Zhu, L.-L., Jiang, S.-H., & Bao, Z. (2019) · Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · doi:10.1016/j.biopha.2019.108856 · Cited by 14
Tracking the important role of JUNB in hepatocellular carcinoma by single‑cell sequencing analysis
Yan, P., Zhou, B., Ma, Y., Wang, A., Hu, X., Luo, Y., Yuan, Y., Wei, Y., Pang, P., & Mao, J. (2019) · Oncology Letters · doi:10.3892/ol.2019.11235 · Cited by 16
Lei, J., Zhang, D., Yao, C., Ding, S., & Lü, Z. (2020) · Cancer Control · doi:10.1177/1073274820977114 · Cited by 16
Sun, L., Lin, Y., Wang, G., Zhang, L., Hu, L., & Lü, Z. (2021) · Bioscience Reports · doi:10.1042/bsr20203115 · Cited by 16
Liao, H., Jiang, H., Chen, Y., Duan, T., Yang, T., Han, M., Xue, Z., Shi, F., Yuan, K., Bashir, M. R., et al. (2022) · Annals of Surgical Oncology · doi:10.1245/s10434-022-11505-4 · Cited by 16
The Tumor Microenvironment in Hepatocellular Carcinoma
Nagaoka, K., Tanaka, Y., & Hino, O. (2022) · Interdisciplinary cancer research · doi:10.1007/16833_2022_66 · Cited by 16
Letter to the editor: the inflamed subclass predicts immunotherapy response – external validations
Li, B., Cao, Y., Li, Y., Cheng, C., & Yu, D. (2022) · Gut · doi:10.1136/gutjnl-2022-328130 · Cited by 16
Li, W. T., Zou, A. E., Honda, C. O., Zheng, H., Wang, X. Q., Kisseleva, T., Chang, E. Y., & Ongkeko, W. M. (2019) · Cancers · doi:10.3390/cancers11091273 · Cited by 15
Identification immunophenotyping of lung adenocarcinomas based on the tumor microenvironment
Tan, Q., Huang, Y., Deng, K., Lu, M., Wang, L., Rong, Z., Zhao, W., Li, S., Xu, Z., Fan, L., et al. (2020) · Journal of Cellular Biochemistry · doi:10.1002/jcb.29675 · Cited by 15
Shi, M., Wang, Y., Tang, W., Cui, X., Wu, H. J., Tang, Y., Wang, P., Wu, W., & Zhang, H. (2020) · Annals of Translational Medicine · doi:10.21037/atm.2020.02.98 · Cited by 15
Yang, Y., Wu, C.-Y., Wang, X., Deng, J., Cao, W.-J., Tang, Y.-Z., Wan, C.-C., Chen, Z.-T., Zhan, W.-Y., Shan, H., et al. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.09.019 · Cited by 16
Zeng, H., Wang, J., Xu, B., Deng, H., Peng, M., Deng, R., Shang, S., Qi, Q., Junjun, J., Lin, J., et al. (2023) · Oncology Reports · doi:10.3892/or.2023.8525 · Cited by 15
Metformin reduces hepatocarcinogenesis by inducing downregulation of Cyp26a1 and CD8+ T cells
He, W., Wang, X., Chen, M., Li, C., Chen, W., Pan, L., Cui, Y., Yu, Z., Wu, G., Yang, Y., et al. (2023) · Clinical and Translational Medicine · doi:10.1002/ctm2.1465 · Cited by 17
Aoki, T., Nishida, N., Kurebayashi, Y., Sakai, K., Fujiwara, N., Tsurusaki, M., Hanaoka, K., Morita, M., Chishina, H., Takita, M., et al. (2025) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2024.1088 · Cited by 21
You, Q., Fang, T., Yin, X., Wang, Y., Yang, Y., Zhang, L., & Xue, Y. (2021) · Journal of Immunology Research · doi:10.1155/2021/6539702 · Cited by 15
The Emerging Role of Tissue-Resident Memory CD8+ T Lymphocytes in Human Digestive Tract Cancers
Mei, X., Li, H., Zhou, X., Cheng, M., & Cui, K. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.819505 · Cited by 16
Muñoz, N. M., Dupuis, C. J., Williams, M. L., Dixon, K. A., McWatters, A., Zhang, J., Pavuluri, S., Rao, A. U. K., Duda, D. G., Kaseb, A. O., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-15948-3 · Cited by 15
Ueno, A., Masugi, Y., Yamazaki, K., Kurebayashi, Y., Tsujikawa, H., Effendi, K., Ojima, H., & Sakamoto, M. (2020) · Pathology International · doi:10.1111/pin.12895 · Cited by 17
Kubo, A., Suda, G., Kimura, M., Maehara, O., Tokuchi, Y., Kitagataya, T., Ohara, M., Yamada, R., Shigesawa, T., Suzuki, K., et al. (2021) · Cancers · doi:10.3390/cancers13143633 · Cited by 14
HBV-HCC treatment with mRNA electroporated HBV-TCR T cells
Tan, A. T., & Bertoletti, A. (2021) · Immunotherapy Advances · doi:10.1093/immadv/ltab026 · Cited by 14
Xu, F., Chen, J., & Huang, D. (2021) · Journal of Cancer · doi:10.7150/jca.65421 · Cited by 14
Fulgenzi, C. A. M., D’Alessio, A., Ogunbiyi, O., Demirtaş, C. Ö., Gennari, A., Cortellini, A., Sharma, R., & Pinato, D. J. (2022) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2072726 · Cited by 14
Motomura, K., Kuwano, A., Tanaka, K., Koga, Y., Masumoto, A., & Yada, M. (2023) · Cancers · doi:10.3390/cancers15174345 · Cited by 14
Chen, Q., Chen, S., Chen, M., Lyu, N., & Zhao, M. D. (2024) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2023.00403 · Cited by 14
γδ T Cells: A Game Changer in the Future of Hepatocellular Carcinoma Immunotherapy
Papadakos, S. P., Arvanitakis, K., Stergiou, I. Ε., Koutsompina, M.-L., Germanidis, G. S., & Theocharis, S. E. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031381 · Cited by 14
Essential roles of B cell subsets in the progression of MASLD and HCC
Petriv, N., Suo, H., Hochnadel, I., Timrott, K., Bondarenko, N., Neubert, L., Reinhard, E., Jedicke, N., Kaufhold, P., Guzmán, C. A., et al. (2024) · JHEP Reports · doi:10.1016/j.jhepr.2024.101189 · Cited by 17
Sun, J., Yuan, H., Sun, L., Zhao, L., Wang, Y., Hou, C., Zhang, H., Lv, P., Yang, G., Zhang, N., et al. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.10.016 · Cited by 14
Identification of a Gene-Related Risk Signature in Melanoma Patients Using Bioinformatic Profiling
Wang, J., Kong, P., Wang, H., Song, D., Wu, W., Zhou, H., Weng, H., Li, M., Kong, X., Meng, B., et al. (2020) · Journal of Oncology · doi:10.1155/2020/7526204 · Cited by 14
Atwa, S., Odenthal, M., & Tayebi, H. M. E. (2021) · Cancers · doi:10.3390/cancers13174343 · Cited by 14
Hamaguchi, K., Miyanishi, K., Osuga, T., Tanaka, S., Ito, R., Sakamoto, H., Kubo, T., Ohnuma, H., Murase, K., Takada, K., et al. (2022) · Cancers · doi:10.3390/cancers14092066 · Cited by 14
The immune landscape of hepatocellular carcinoma‑where we are? (Review)
Gryziak, M., Woźniak, K., Kraj, L., Róg, L., & Stec, R. (2022) · Oncology Letters · doi:10.3892/ol.2022.13530 · Cited by 14
Intratumoral heterogeneity and clonal evolution in liver cancer
Losic, B., Craig, A., Villacorta-Martin, C., Martins-Filho, S., Akers, N. K., Xin-Wen, C. H. E. N., Ahsen, M., von Felden, J., Labgaa, I., D’Avola, D., et al. (2020) · immuneACCESS · doi:10.21417/bl2020nc · Cited by 18
Self-citationElmetwalli, A. (2025) · Drug Resistance Updates · doi:10.1016/j.drup.2025.101326 · Cited by 16
Mutational scanning reveals oncogenic CTNNB1 mutations have diverse effects on signaling
Krishna, A., Meynert, A. M., Dolt, K. S., Kelder, M. J. E., Mesropian, A., Ewing, A., Brouwers, C. M., Claassens, J. W. C., Linssen, M. M. L., Sheraz, S., et al. (2026) · Nature Genetics · doi:10.1038/s41588-025-02496-5 · Cited by 14
Self-citationPrecision Medicine of Hepatobiliary and Pancreatic Cancers: Focusing on Clinical Trial Outcomes
Tsumura, T., Doi, K., & Marusawa, H. (2022) · Cancers · doi:10.3390/cancers14153674 · Cited by 15
Meng, Y., Zhang, M., Li, X., Wang, X., Dong, Q., Zhang, H., Zhai, Y., Song, Q., He, F., Tian, C., et al. (2024) · International Journal of Biological Sciences · doi:10.7150/ijbs.91877 · Cited by 13
Yang, F., Deng, K., Zheng, H., Liu, Z., & Zheng, Y. (2022) · Annals of Hepatology · doi:10.1016/j.aohep.2022.100677 · Cited by 13
Biomarker Development Using Liquid Biopsy in Hepatocellular Carcinoma
Grinspan, L. T., & Villanueva, A. (2022) · Seminars in Liver Disease · doi:10.1055/s-0042-1748924 · Cited by 13
Self-citationLiver Fibrosis, Liver Cancer, and Advances in Therapeutic Approaches
Rajapaksha, I. G. (2022) · Livers · doi:10.3390/livers2040028 · Cited by 14
Transcriptional Regulation of Siglec-15 by ETS-1 and ETS-2 in Hepatocellular Carcinoma Cells
Sheng, K., Wu, Y., Lin, H., Fang, M., Xue, C., Xu, L., & Lin, X. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24010792 · Cited by 13
Zou, X., Xu, Q., You, R., & Yin, G. (2023) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s399874 · Cited by 13
Nakajima, M., Hazama, S., Tokumitsu, Y., Shindo, Y., Matsui, H., Matsukuma, S., Nakagami, Y., Tamada, K., Udaka, K., Sakamoto, M., et al. (2023) · Hepatology Research · doi:10.1111/hepr.13900 · Cited by 15
Advances in Immunotherapy for Hepatocellular Carcinoma
Hagiwara, S., Nishida, N., & Kudo, M. (2023) · Cancers · doi:10.3390/cancers15072070 · Cited by 13
Combined immunotherapy and VEGF-antagonist in hepatocellular carcinoma: a step forward
Bhoori, S., & Mazzaferro, V. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30211-4 · Cited by 14
Self-citationJiang, H., Wei, H., Liang, L., Wang, Y., Kuang, M., Ronot, M., Song, B., & Lee, J. M. (2025) · Liver Cancer · doi:10.1159/000546966 · Cited by 15
Weinfurtner, K. M., Cho, H. J., Ackerman, D., Chen, J. X., Woodard, A., Li, W., Ostrowski, D., Soulen, M. C., Dagli, M. S., Shamimi-Noori, S. M., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-02093-6 · Cited by 12
Lacotte, S., Slits, F., Moeckli, B., Peloso, A., Koenig, S., Tihy, M., Hajji, S. E., Gex, Q., Rubbia‐Brandt, L., & Toso, C. (2023) · OncoImmunology · doi:10.1080/2162402x.2023.2184991 · Cited by 14
Ding, R., Wang, Y., Fan, J., Tian, Z., Wang, S., Qin, X., Su, W. C., & Wang, Y. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1108472 · Cited by 12
Liver resection and transplantation in the era of checkpoint inhibitors
Tabrizian, P., Marino, R., & Chow, P. K. H. (2024) · JHEP Reports · doi:10.1016/j.jhepr.2024.101181 · Cited by 15
Porreca, V., Barbagallo, C., Corbella, E., Peres, M., Stella, M., Mignogna, G., Maras, B., Ragusa, M., & Mancone, C. (2024) · Cancers · doi:10.3390/cancers16162889 · Cited by 13
Ercan, C., Renne, S. L., Tommaso, L. D., Ng, C. K. Y., Piscuoglio, S., & Terracciano, L. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-0960 · Cited by 14
Ueshima, E., Sofue, K., Kodama, T., Yamamoto, S., Komatsu, M., Komatsu, S., Ishihara, N., Umeno, A., Yamaguchi, T., Hori, M., et al. (2024) · Liver Cancer · doi:10.1159/000542099 · Cited by 12
Immunosenescence and immunotherapy in elderly patients with hepatocellular carcinoma
Zhang, D., Zhu, Y., Shen, Z., Ma, S., Liu, S., & Lu, Z. (2025) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2025.02.010 · Cited by 12
The Genomic Landscape and Its Clinical Implications in Hepatocellular Carcinoma
Yim, S. Y., & Lee, J. (2019) · Journal of Liver Cancer · doi:10.17998/jlc.19.2.97 · Cited by 12
Li, Y., Lu, S., Wang, S., Peng, X., & Lang, J. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-021-02894-3 · Cited by 12
Desquilles, L., Cano, L., Ghukasyan, G., Mouchet, N., Landreau, C., Corlu, A., Clément, B., Turlin, B., Désert, R., & Musso, O. C. (2022) · Scientific Reports · doi:10.1038/s41598-021-03710-0 · Cited by 12
Lu, G., Du, R., Feng, B., Wang, J., Zhang, F., Pei, J., Wang, Y., & Shang, Y. (2022) · Journal of Inflammation Research · doi:10.2147/jir.s390113 · Cited by 11
Rizzo, A., Ricci, A. D., Fanizzi, A., Massafra, R., Luca, R. D., & Brandi, G. (2023) · Current Oncology · doi:10.3390/curroncol30010057 · Cited by 13
New Opportunities to Individualize Frontline Therapy in Advanced Stages of Hepatocellular Carcinoma
Gordan, J. D., Keenan, B. P., Lim, H. C., Yarchoan, M. M., & Kelley, R. K. (2023) · Drugs · doi:10.1007/s40265-023-01907-3 · Cited by 12
Martins-Filho, S. N., & Alves, V. A. F. (2019) · Surgical and Experimental Pathology · doi:10.1186/s42047-019-0047-6 · Cited by 12
Gül‐Klein, S., Kästner, A., Haber, P. K., Krenzien, F., Wabitsch, S., Krannich, A., Andreou, A., Eurich, D., Tacke, F., Horst, D. A., et al. (2021) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s292010 · Cited by 12
Chen, D., Li, X., Li, H., Wang, K., & Tian, X. (2022) · Journal of Oncology · doi:10.1155/2022/5313149 · Cited by 12
Immunotherapy and Hepatocellular Cancer: Where Are We Now?
Valéry, M., Cervantes, B., Samaha, R., Gelli, M., Smolenschi, C., Fuerea, A. C., Tselikas, L., Prieux‐Klotz, C., Hollebecque, A., Boige, V., et al. (2022) · Cancers · doi:10.3390/cancers14184523 · Cited by 13
Marquardt, J. U. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.11.015 · Cited by 12
Epigenetic mechanisms in HCC immune landscape: Therapeutic implications
Fernández‐Barrena, M. G., Uriarte, I., Sarobe, P., & Avila, M. A. (2025) · Seminars in Immunology · doi:10.1016/j.smim.2025.101980 · Cited by 14
Jiang, K., Zhu, L., Huang, H., Liu, Z., Wang, Z., & Kang, X. (2023) · Cellular Oncology · doi:10.1007/s13402-023-00861-2 · Cited by 11
Chen, Y., Yang, C., Sheng, L., Jiang, H., & Song, B. (2023) · Cancers · doi:10.3390/cancers15194677 · Cited by 11
Dantzer, C., Vaché, J., Brunel, A., Mahouche, I., Raymond, A., Dupuy, J., Petrel, M., Bioulac‐Sage, P., Perrais, D., Dugot‐Senant, N., et al. (2024) · eLife · doi:10.7554/elife.95191.3 · Cited by 11
Lin, X., Shao, H., Tang, Y., Wang, Q., Yang, Z., Wu, H., & Xing, T. (2024) · Aging · doi:10.18632/aging.206020 · Cited by 11
Li, C., Li, X., Niu, M., Xiao, D.-K., Luo, Y., Wang, Y., Fang, Z.-E., Zhan, X., Zhao, X., Fang, M., et al. (2024) · Chinese Medicine · doi:10.1186/s13020-024-01003-y · Cited by 10
Grieb, B. C., Goff, L. W., Goyal, L., & Denlinger, C. S. (2019) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_237555 · Cited by 11
Hatanaka, T., Kakizaki, S., Nagashima, T., Namikawa, M., Ueno, T., Tojima, H., Takizawa, D., Naganuma, A., Arai, H., Harimoto, N., et al. (2021) · Oncology · doi:10.1159/000517494 · Cited by 11
Ji, F., Yuan, J.-M., Gao, H., Xu, A.-Q., Yang, Z., Yang, C.-Q., Zhang, L., Yang, M., Li, J., Zhu, T., et al. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.759495 · Cited by 11
Hu, Y., Liu, J., Yu, J., Yang, F., Zhang, M., Liu, Y., Ma, S., Zhou, X., Wang, J., & Han, Y. (2022) · Cancer Cell International · doi:10.1186/s12935-022-02514-0 · Cited by 11
Approaches to spatially resolving the tumour immune microenvironment of hepatocellular carcinoma
Marsh‐Wakefield, F., Ferguson, A. L., Liu, K., Santhakumar, C., McCaughan, G. W., & Palendira, U. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221113270 · Cited by 11
Aging-related features predict prognosis and immunotherapy efficacy in hepatocellular carcinoma
Hong, T., Su, W., Pan, Y., Tian, C., & Lei, G. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.951459 · Cited by 11
Costante, F., Airola, C., Santopaolo, F., Gasbarrini, A., Pompili, M., & Ponziani, F. R. (2022) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v14.i9.1622 · Cited by 12
Chemokine CCL5 immune subtypes of human liver cancer with prognostic significance
Xia, Y., Zhou, L., Yang, H., & Yu, D. C. W. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109372 · Cited by 11
Alpha‐fetoprotein in liver transplantation for hepatocellular carcinoma: The lower, the better
Mazzaferro, V., Busset, M. D. D., & Bhoori, S. (2018) · Hepatology · doi:10.1002/hep.29835 · Cited by 11
Self-citationKabashima, A., Shimada, S., Shimokawa, M., Akiyama, Y., Tanabe, M., & Tanaka, S. (2020) · Journal of Hepato-Biliary-Pancreatic Sciences · doi:10.1002/jhbp.874 · Cited by 11
Immunological characterization of hepatocellular carcinoma
Wang, S. Z., Lee, S. D., Sarkar, D., Lee, H. M., Khan, A. A., Bhati, C. S., Sharma, A., Kumaran, V., Bruno, D., COTTERELL, A. H., et al. (2021) · Hepatoma Research · doi:10.20517/2394-5079.2020.113 · Cited by 11
Sukowati, C. H. C., El-Khobar, K. E., & Tiribelli, C. (2021) · World Journal of Stem Cells · doi:10.4252/wjsc.v13.i7.795 · Cited by 11
Identification of immune-related subtypes of colorectal cancer to improve antitumor immunotherapy
Zheng, X., Gao, Y., Yu, C., Fan, G., Li, P., Zhang, M., Yu, J., & Xu, M. (2021) · Scientific Reports · doi:10.1038/s41598-021-98966-x · Cited by 11
Kaya, N. A., Chen, J., Lai, H. L. H., Yang, H., Ma, L., Liu, X., Alvarez, J. J. S., Liu, J., Hillmer, A. M., Tai, D. W.-M., et al. (2022) · Theranostics · doi:10.7150/thno.71676 · Cited by 10
Martins-Filho, S. N., Alves, V. A. F., Wakamatsu, A., Maeda, M., Craig, A. J., Assato, A. K., Villacorta-Martín, C., D’Avola, D., Labgaa, I., Carrilho, F. J., et al. (2019) · Histopathology · doi:10.1111/his.13809 · Cited by 11
Self-citation
Metadata
- Authors
- Sia, D., Jiao, Y., Martinez-Quetglas, I., Kuchuk, O., Villacorta-Martin, C., Castro de Moura, M., Putra, J., Camprecios, G., Bassaganyas, L., Akers, N., Losic, B., Waxman, S., Thung, S. N., Mazzaferro, V., Esteller, M., Friedman, S. L., Schwartz, M., Villanueva, A., & Llovet, J. M.
- Affiliations
- Tisch Cancer Institute (US)
- Hospital Clínic de Barcelona (ES)
- University of Milan (IT)
- Institució Catalana de Recerca i Estudis Avançats (ES)
- Corresponding author
- Llovet, Josep M.
- ORCID
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 2017-09
- Volume
- 153
- Issue
- 3
- Pages
- 812-826
- ISSN
- 0016-5085 (ISSN-L)
- PMC
- PMC12166766
- OpenAlex
- W2626033245
- Cited by
- 976
- References
- 46
- Citations by year
- 2026: 65 · 2025: 82 · 2024: 124 · 2023: 136 · 2022: 155 · 2021: 188 · 2020: 104 · 2019: 72 · 2018: 41 · 2017: 9
- FWCI
- 27.37
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Gastroenterology (acceptedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (acceptedVersion, cc-by-nc-nd)
- Funders
- Tisch Cancer Institute (P30 CA196521)
- US Department of Defense (CA150272P3)
- European Commission Framework Program 7 (259744)
- Horizon 2020 Program (667273–2)
- Asociación Española Contra el Cáncer
- Samuel Waxman Cancer Research Foundation
- Spanish National Health Institute (SAF2013–41027)
- Grup de Recerca Consolidat–Recerca Translacional en Oncologia Hepàtica
- AGAUR (SGR 1162)
- European Commission HEPCAR
- Onlus Prometeo
- Hepato-Oncology Research Project
- Istituto Nazionale Tumori
- National Cancer Institute
- IRCCS Foundation
- Juan de la Cierva Fellowship
- Associazione Italiana per la Ricerca sul Cancro
- Italian Ministry of Health
- National Institutes of Health (R01DK56621)
- American Association
- Liver Diseases Foundation Alan Hofmann Clinical and Translational Award
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Health Sciences › Medicine › Epidemiology › Hepatitis B Virus Studies
- Keywords
- hepatocellular carcinoma, tumor immune microenvironment, immune cell infiltration, PD-1, T cell exhaustion, TGF-β1, chromosomal abnormalities, cancer mutations, tumor-infiltrating immune cells, immune checkpoint inhibitors, tumor subtypes, gene expression profiling, non-negative matrix factorization, tides
- MeSH terms
- Aged, Female, Carcinoma, Hepatocellular, Humans, Immune Tolerance, Immunohistochemistry, Liver Neoplasms, Male, Middle Aged, Mutation, Signal Transduction, Gene Expression Regulation, Neoplastic, Immunophenotyping, Lymphocytes, Tumor-Infiltrating, DNA Methylation, beta Catenin, Transforming Growth Factor beta1, Adaptive Immunity, Tumor Microenvironment, Transcriptome, B7-H1 Antigen, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
